Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Low-Dose immune therapy restore hair in severe alopecia?

NCT ID NCT02557074

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether low doses of interleukin-2 (IL2) can help people with severe alopecia areata, a condition causing patchy or total hair loss. 44 adults with at least 50% scalp hair loss who had not responded to other treatments received either IL2 injections or a placebo. The main goal was to see if hair regrowth reached a certain level (SALT score ≤25) after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose interleukin-2 (IL2)
What this could lead to
If it works, this could provide a new treatment option for people with severe alopecia areata who haven't responded to other therapies.
What could go wrong
This is a small Phase 3 trial with only 44 participants, so results may not apply to everyone. The treatment involves injections and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

44 people

The number who actually took part.

Started

Dec 2015

Finished

Dec 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Of more than 18 years old, * Affiliated to the social security system, * Clinical diagnosis of alopecia areata, * 50 % of the surface of the scalp affected * Last flaire started less than one year * Alopecia areata resisting to at least 1 systematic treatment including phototherapy (UVB or PUVA), general corticosteroid therapy or methotrexate * Signature of the informed consent Exclusion Criteria: * Pregnancy or refusal of contraception at the women old enough to procreate, * Refusal of contraception at the men * Local treatment (dermocorticoïdes, minoxidil) or systematism (oral corticosteroid therapy, méthotrexate or the other immunosuppresseur) since less than 2 less, * Evolutionary autoimmune cancer or disease or in forgiveness * Excessive grip(taking) of alcohol (upper to 3 glasses of wine a day or one pre-lunch drink a day) * Seropositivity VHC, VHB, or HIV * Patient presenting a severe renal and/or hepatic insufficiency, * Presenting patient one zoned, the chicken pox, the herpes, the tuberculosis, an evolutionary infectious disease, a respiratory failure … * Vulnerable person (nobody under guardianship minor(miner), adults, deprived of freedom) * IC in the treatment(processing) by IL-2R * Presenting a contraindication to ProleukinR

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

Contacts and locations

Locations

  • AP-HM - La timone - Dermatologie

    Marseille, Bouche Du Rhône, 13005, France

  • AP-HP St Louis - Dermatologie

    Paris, Île-de-France Region, 75000, France

  • CHI St Raphael Fréjus - Dermatologie

    Fréjus, PACA, 83000, France

  • CHU Montpellier - Dermatologie

    Montpellier, 34000, France

  • CHU de Nice - dermatologie

    Nice, 06200, France

  • CHU de Nimes - Dermatologie

    Nîmes, Languedoc-Roussillon, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.